Apnoeas in bronchiolitis: Is there a role for caffeine? [5]

Archives of Disease in Childhood

Volumn 90, Issue 4, 2005, Pages 438-

  Sajit, N T ^a   Steggall, M ^a   Padmakumar, B ^a  

^a ROYAL OLDHAM HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; RESPIRATORY STIMULANT AGENT;

APNEA; ASSISTED VENTILATION; BRONCHIOLITIS; CLINICAL ARTICLE; DISEASE ASSOCIATION; HUMAN; INTENSIVE CARE UNIT; LETTER; PRIORITY JOURNAL; QUESTIONNAIRE; TREATMENT OUTCOME; UNITED KINGDOM; WINTER;

APNEA; BRONCHIOLITIS; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; INFANT;

EID: 16844374626     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2004.064824     Document Type: Letter

References (3)

1. Kneyber MC, Brandenberg AH, de Groot R, et al. Risk factors for respiratory syncytial virus associated apnoea. Eur J Pediatr 1998;157:331-5.
2. Henderson-Smart DJ, Steer PA. Prophylactic methylxanthine far preventing of apnea in preterm infants. Cochrane Database Syst Rev 2000;2:CD000432.
3. Tobias JD. Caffeine in the treatment of apnea associated with respiratory syncytial virus infection in neonates and infants. South Med J 2000;93:294-6.